Part of TopicBrowse Topic in full-screen mode
The overall response rate was 0% (9/9) with all patients progressing on treatment at the time of their first assessment imaging. Kaplan Meier estimate of median progression free survival was 2.0 months (95% CI 1.6-2.4) and mean overall survival was 4.5 months (95% CI 3.1-5.8). Median survival was not reached due to short follow-up but by 4 months, 45% of patient had died.
Toxicity data using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0 showed 58% (7/12) had no toxicities; lethargy in 8% (1/12), neutropenia in 17% (2/12); nausea 8%(1/12) and deranged liver functions test in 8% (1/12).